Inoue Y, Takata K, Sakamoto I, Hazama H, Kawahara R
Department of Neuropsychiatry, Faculty of Medicine, Tottori University, Yonago, Japan.
Psychiatry Clin Neurosci. 1999 Apr;53(2):321-2. doi: 10.1046/j.1440-1819.1999.00551.x.
The efficacy and indication of acetazolamide treatment on patients with sleep apnea syndrome (SAS) were discussed from assessing the changes of polysomnographic findings with the treatment in 75 SAS patients. For the patients as a whole, respiratory disorder variables improved significantly during the treatment. However, the number of acetazolamide treatment responders who showed a decrease of apnea hypopnea index (AHI) to 50% or less of the pretreatment value numbered only 34 (45.3%). The lower values of body mass index and AHI in the responder group indicated that monotherapy with acetazolamide is the treatment choice only for mild SAS cases without obesity. However, combined treatment with acetazolamide and uvulopalatopharyngoplasty was thought to be beneficial for severe cases.
